Search
Showing results for "lung disease preterm"
Citation: Evans DJ, D Sly PD, Foster P, Donovan C. Who gets asthma, and why? Med J Aust. 2025;223(S10):S19-S23. Keywords: Asthma; Lung diseases;
The most urgent areas appear to be to continue monitoring the emergence of novel otopathogens, and the need to develop prevention and preventative therapies
Community links and support services
Clinical utility of home polysomnography in children with neuromuscular disorders is limited by lack of evidence that sleep-disordered breathing can be reliably identified and inability to diagnose hypoventilation because carbon dioxide is not measured.
Wal-yan Respiratory Research Centre team members and special guests travelled to Wadjemup (Rottnest) on 27 and 28 October to spend an intensive two days together learning about, and providing input into, the broad range of research projects underway within the Centre.
Here are some of the most common questions about phage, phage therapy and antimicrobial resistance (AMR).
Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.
We are looking for Aboriginal parents who are passionate about lung health to join the Aboriginal Advisory Committee (AAC) for our Kids Easy Breathing Study (KEBS). Research shows 1 in 5 Aboriginal* bubs in hospital for bronchiolitis (a common viral chest infection) later had serious damage to their lungs. The aim of our study is to find out why Aboriginal bubbies are more likely to develop long-term lung sickness.
Two international trials led by The Kids Research Institute Australia’s Neonatal and Infection Immunity Team are tackling the urgent need for simple and safe interventions that can help prevent the adverse long-term effects of infections in extremely preterm babies.
A telehealth-facilitated randomised-controlled trial utilising a health promotion intervention to resolve otitis media with effusion for children won specialist Ear, Nose and Throat (ENT) waiting lists